Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway

Cell Cycle

Volumn 12, Issue 18, 2013, Pages 3109-3124

  Corominas Faja, Bruna ^a,b   Cufí, Sílvia ^a,b   Oliveras Ferraros, Cristina ^a,b   Cuyàs, Elisabet ^a,b   López Bonet, Eugeni ^c   Lupu, Ruth ^d   Alarcón, Tomás ^e   Vellon, Luciano ^f   Iglesias, Juan Manuel ^f   Leis, Olatz ^f   Martín, Ángel G ^f   Vazquez Martin, Alejandro ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d MAYO CLINIC CANCER CENTER   (United States)

^e CENTRE DE RECERCA MATEMÀTICA   (Spain)

^f Biomedical Research and Technological Development Institute   (Spain)

Author keywords

AMPK; Breast cancer; Cancer stem cells; MTOR; Reprogramming; SOX2

Indexed keywords

ALKALINE PHOSPHATASE; FATTY ACID SYNTHASE; HERMES ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; KRUPPEL LIKE FACTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 1; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TUMOR REJECTION ANTIGEN; TUMOR REJECTION ANTIGEN 1-60; TUMOR REJECTION ANTIGEN 1-81; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CATABOLISM; CELL DIFFERENTIATION; CELL POPULATION; DDIT4 GENE; DEPTOR GENE; DOWN REGULATION; ENZYME ACTIVITY; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRKAA1 GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; UPREGULATION;

AMPK; BREAST CANCER; CANCER STEM CELLS; MTOR; REPROGRAMMING; SOX2;

AMP-ACTIVATED PROTEIN KINASES; BREAST NEOPLASMS; DOWN-REGULATION; FATTY ACID SYNTHASE, TYPE I; FEMALE; HUMANS; KINESIN; MCF-7 CELLS; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, INSULIN; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOXB1 TRANSCRIPTION FACTORS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84884849331     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26173     Document Type: Article

References (100)

1. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006; 66:1883-90, discussion 1895-6; PMID:16488983; http://dx.doi.org/10.1158/0008-5472.CAN-05-3153
2. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26:2813-20; PMID:18539959; http://dx.doi.org/10.1200/JCO.2008.16.3931
3. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005; 7:86-95; PMID:15987436; http://dx.doi.org/10.1186/bcr1021
4. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) 2010; 3:1361-4; PMID:20959519; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0234
5. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21:283-96; PMID:22439924; http://dx.doi.org/10.1016/j.ccr.2012.03.003
6. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146:633-44; PMID:21854987; http://dx.doi.org/10.1016/j.cell.2011.07.026
7. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011; 108:7950-5; PMID:21498687; http://dx.doi.org/10.1073/pnas.1102454108
8. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011; 108:1397-402; PMID:21220315; http://dx.doi.org/10.1073/pnas.1018898108
9. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A 2012; 109:14470-5; PMID:22908280; http://dx.doi.org/10.1073/pnas. 1212811109
10. Abollo-Jiménez F, Jiménez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010; 20:98-106; PMID:20188173; http://dx.doi.org/10.1016/j.semcancer.2010.02.002
11. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011; 13:R94; PMID:21952072; http://dx.doi.org/10.1186/bcr3019
12. Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, Kimura H, Perrem K, Umezawa A, Yamamoto N, et al. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene 2013; PMID:23318426; http://dx.doi.org/10.1038/ onc.2012.614
13. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143:508-25; PMID:21074044; http://dx.doi.org/10.1016/j.cell.2010.10.008
14. Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res 2011; 21:486-501; PMID:21321600; http://dx.doi.org/10.1038/cr.2011.28
15. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008; 100:133-58; PMID:18620095; http://dx.doi.org/10.1016/S0065- 230X(08)00005-5
16. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009; 27:1050-6; PMID:19415771; http://dx.doi.org/10.1002/stem.37
17. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11:268-77; PMID:21390058; http://dx.doi.org/10.1038/nrc3034
18. Castellanos A, Vicente-Dueñas C, Campos-Sánchez E, Cruz JJ, García-Criado FJ, García-Cenador MB, Lazo PA, Pérez-Losada J, Sánchez-García I. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol 2010; 20:93-7; PMID:20188174; http://dx.doi.org/10.1016/j.semcancer.2010.02.001
19. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi.org/10.4161/ cc.10.21.18128
20. Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol 2009; 27:281-7; PMID:19252483; http://dx.doi.org/10.1038/nbt.1527
21. Menendez S, Camus S, Herreria A, Paramonov I, Morera LB, Collado M, Pekarik V, Maceda I, Edel M, Consiglio A, et al. Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell 2012; 11:41-50; PMID:21981310; http://dx.doi.org/10. 1111/j.1474-9726.2011.00754.x
22. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 2010; 28:721-33; PMID:20201066; http://dx.doi.org/10.1002/stem.404
23. Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA 4th, Ramalho-Santos J, Van Houten B, Schatten G. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 2011; 6:e20914; PMID:21698063; http://dx.doi.org/10.1371/journal.pone.0020914
24. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, Ralser M, Timmermann B, Adjaye J. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells 2011; 29:1338-48; PMID:21732474
25. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, Herrerías A, Batchelder EM, Plongthongkum N, Lutz M, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22:168-77; PMID:22064701; http://dx.doi.org/10.1038/cr.2011.177
26. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, Ikeda Y, Perez-Terzic C, Terzic A. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10. 1016/j.cmet.2011.06.011
27. Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming. Biomark Med 2011; 5:715-29; PMID:22103608; http://dx.doi.org/10. 2217/bmm.11.87
28. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci 2012; 1254:82-9; PMID:22548573; http://dx.doi.org/10.1111/j.1749-6632.2012.06487.x
29. Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 2013; 22:37-50; PMID:22998387; http://dx.doi.org/10.1089/scd.2012.0375
30. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, Martin AG, Martin-Castillo B, López-Otín C, Menendez JA. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 2012; 11:974-89; PMID:22333578; http://dx.doi.org/10. 4161/cc.11.5.19450
31. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) 2012; 4:393-401; PMID:22713507
32. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin- Castillo B, Menendez JA. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep 2012; 2:964; PMID:23236586; http://dx.doi.org/10.1038/srep00964
33. Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, Joven J, Lupu R, Menendez JA. The mitochondrial H(+)- ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle 2013; 12:207-18; PMID:23287468; http://dx.doi.org/10.4161/cc.23352
34. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F, Wang C, Wolvetang E, Vazquez-Martin A, Zhang J. Autophagy in stem cells. [Epub ahead of print]. Autophagy 2013; 9:830-49; PMID:23486312; http://dx.doi.org/10.4161/auto. 24132
35. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12:1166-79; PMID:23549172; http://dx.doi.org/10.4161/cc.24479
36. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25:1895-908; PMID:21937710; http://dx.doi.org/10.1101/gad.17420111
37. Hardie DG. Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection. Cold Spring Harb Symp Quant Biol 2011; 76:155-64; PMID:22071265; http://dx.doi.org/10.1101/sqb.2011.76.010819
38. Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011; 93:891S-6; PMID:21325438; http://dx.doi.org/10. 3945/ajcn.110.001925
39. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18:2893-904; PMID:15545625; http://dx.doi.org/10.1101/gad.1256804
40. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005; 25:5834-45; PMID:15988001; http://dx.doi.org/10.1128/MCB.25.14.5834-5845.2005
41. Kimball SR, Do AN, Kutzler L, Cavener DR, Jefferson LS. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem 2008; 283:3465-75; PMID:18070882; http://dx.doi.org/10.1074/jbc. M706643200
42. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti- Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71:4366-72; PMID:21540236; http://dx.doi.org/10.1158/0008-5472.CAN-10-1769
43. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012; 11:2391-401; PMID:22627671; http://dx.doi.org/10.4161/cc.20683
44. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137:873-86; PMID:19446321; http://dx.doi.org/10.1016/j.cell.2009.03.046
45. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, Deng C, Dong LQ, Liu F. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 2010; 285:36387-94; PMID:20851890; http://dx.doi.org/10. 1074/jbc.M110.169284
46. Wang Z, Zhong J, Inuzuka H, Gao D, Shaik S, Sarkar FH, Wei W. An evolving role for DEPTOR in tumor development and progression. Neoplasia 2012; 14:368-75; PMID:22745583
47. Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, et al.; DIAGRAM Consortium; MAGIC Investigators. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011; 147:81-94; PMID:21962509; http://dx.doi.org/10.1016/j.cell.2011.08.033
48. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7:1003-15; PMID:21912508; http://dx.doi.org/10.7150/ijbs.7.1003
49. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12:159-69; PMID:22337149
50. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 2011; 130:387-98; PMID:21188630; http://dx.doi.org/10.1007/s10549-010-1300-6
51. Pandey PR, Xing F, Sharma S, Watabe M, Pai SK, Iiizumi-Gairani M, Fukuda K, Hirota S, Mo YY, Watabe K. Elevated lipogenesis in epithelial stemlike cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene 2012; PMID:23208501; http://dx.doi.org/10.1038/onc.2012.519
52. Li G, Zhao F, Cui Y. Proteomics using mammospheres as a model system to identify proteins deregulated in breast cancer stem cells. Curr Mol Med 2013; 13:459-63; PMID:23331018
53. Yecies JL, Manning BD. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 2011; 71:2815-20; PMID:21487041; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-4158
54. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011; 14:21-32; PMID:21723501; http://dx.doi.org/10.1016/j.cmet.2011.06. 002
55. Bakan I, Laplante M. Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 2012; 23:226-34; PMID:22449814; http://dx.doi.org/10.1097/MOL. 0b013e328352dd03
56. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146:408-20; PMID:21816276; http://dx.doi.org/10.1016/j.cell.2011.06.034
57. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507; PMID:18443585; http://dx.doi.org/10.1038/ng.127
58. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, Lehrach H, Burdon T, Adjaye J. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2007; 25:500-10; PMID:17068183; http://dx.doi.org/10.1634/stemcells.2006- 0426
59. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121:465-77; PMID:15882627; http://dx.doi.org/10.1016/j.cell. 2005.02.018
60. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010; 29:2153-9; PMID:20101213; http://dx.doi.org/10.1038/onc.2009.500
61. Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 2008; 68:6533-40; PMID:18701476; http://dx.doi.org/10.1158/0008-5472.CAN-07-6642
62. Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 2012; 18:245-7; PMID:22521522; http://dx.doi.org/10.1016/j.molmed.2012.04.001
63. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 2010; 107:40-5; PMID:20018687; http://dx.doi.org/10.1073/pnas.0912407107
64. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013; 32( 2260.e1-21):2249-60, e1-21; PMID:22777357; http://dx.doi.org/10.1038/onc.2012.237
65. Liu X, Sun H, Qi J, Wang L, He S, Liu J, Feng C, Chen C, Li W, Guo Y, et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol 2013; 15:829-38; PMID:23708003; http://dx.doi.org/10.1038/ncb2765
66. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011; 30:2161-72; PMID:21242971; http://dx.doi.org/10.1038/onc.2010.591
67. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7:R220-8; PMID:15743499; http://dx.doi.org/10.1186/bcr975
68. Li R, Liang J, Ni S, Zhou T, Qing X, Li H, He W, Chen J, Li F, Zhuang Q, et al. A mesenchymal-toepithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7:51-63; PMID:20621050; http://dx.doi.org/10.1016/j.stem.2010.04.014
69. Redmer T, Diecke S, Grigoryan T, Quiroga-Negreira A, Birchmeier W, Besser D. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBO Rep 2011; 12:720-6; PMID:21617704; http://dx.doi.org/10.1038/embor.2011.88
70. Lowry WE. E-cadherin, a new mixer in the Yamanaka cocktail. EMBO Rep 2011; 12:613-4; PMID:21701504; http://dx.doi.org/10.1038/embor.2011.117
71. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31:1354-65; PMID:21822303; http://dx.doi.org/10.1038/onc.2011.338
72. Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJ, Hsu TL, et al. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A 2013; 110:2517-22; PMID:23355685; http://dx.doi.org/10.1073/pnas.1222649110
73. Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol 2010; 222:335-44; PMID:20848663; http://dx.doi.org/10.1002/path.2772
74. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011; 10:1378-84; PMID:21552008; http://dx.doi.org/10.4161/cc.10.9.15486
75. Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8 T cells. Clin Cancer Res 2011; 17:6174-84; PMID:21856769; http://dx.doi.org/10.1158/1078-0432.CCR-11- 1111
76. Badve S, Nakshatri H. Breast-cancer stem cellsbeyond semantics. Lancet Oncol 2012; 13:e43-8; PMID:22225725; http://dx.doi.org/10.1016/S1470-2045(11) 70191-7
77. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, Truong KD, Phan NK. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011; 9:209; PMID:22152097; http://dx.doi.org/10.1186/1479-5876-9-209
78. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013; 238:324-38; PMID:23598979; http://dx.doi.org/10.1177/ 1535370213480714
79. Wu F, Zhang J, Wang P, Ye X, Jung K, Bone KM, Pearson JD, Ingham RJ, McMullen TP, Ma Y, et al. Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cell Signal 2012; 24:1989-98; PMID:22800865; http://dx.doi.org/10.1016/j.cellsig.2012.07.008
80. Wu F, Ye X, Wang P, Jung K, Wu C, Douglas D, Kneteman N, Bigras G, Ma Y, Lai R. Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity. BMC Cancer 2013; 13:317; PMID:23815808; http://dx.doi.org/10.1186/1471-2407-13-317
81. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17:113-24; PMID:23274086; http://dx.doi.org/10.1016/j.cmet.2012.12.001
82. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460:1140-4; PMID:19668186; http://dx.doi.org/10.1038/nature08311
83. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460:1149-53; PMID:19668189; http://dx.doi.org/10.1038/nature08287
84. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460:1145-8; PMID:19668190; http://dx.doi.org/10.1038/nature08285
85. Liu Y, Hoya-Arias R, Nimer SD. The role of p53 in limiting somatic cell reprogramming. Cell Res 2009; 19:1227-8; PMID:19881523; http://dx.doi.org/10. 1038/cr.2009.121
86. He J, Kang L, Wu T, Zhang J, Wang H, Gao H, Zhang Y, Huang B, Liu W, Kou Z, et al. An elaborate regulation of Mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors. Stem Cells Dev 2012; 21:2630-41; PMID:22471963; http://dx.doi.org/10. 1089/scd.2012.0015
87. Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY, Lee WH. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011; 30:2463-74; PMID:21258409; http://dx.doi.org/10.1038/onc.2010.618
88. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 2011; 130:387-98; PMID:21188630; http://dx.doi.org/10.1007/s10549-010-1300-6
89. Malaguarnera R, Frasca F, Garozzo A, Gianì F, Pandini G, Vella V, Vigneri R, Belfiore A. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab 2011; 96:766-74; PMID:21123448; http://dx.doi.org/10.1210/jc.2010-1255
90. Savarese TM, Low HP, Baik I, Strohsnitter WC, Hsieh CC. Normal breast stem cells, malignant breast stem cells, and the perinatal origin of breast cancer. Stem Cell Rev 2006; 2:103-10; PMID:17237548; http://dx.doi.org/10.1007/ s12015-006-0016-9
91. Ginestier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res 2007; 9:109; PMID:17688678; http://dx.doi.org/10.1186/bcr1741
92. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissuespecific stem cells. Breast Cancer Res 2005; 7:13-7; PMID:15642176; http://dx.doi.org/ 10.1186/bcr966
93. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 2010; 64:628-36; PMID:20201993; http://dx.doi.org/10.1111/j.1742-1241.2010.02354.x
94. Zhang G, Yang P, Guo P, Miele L, Sarkar FH, Wang Z, Zhou Q. Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. Biochim Biophys Acta 2013; 1836:49-59; PMID:23523716
95. Rafalski VA, Mancini E, Brunet A. Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate. J Cell Sci 2012; 125:5597-608; PMID:23420198; http://dx.doi.org/10.1242/jcs.114827
96. Martí M, Mulero L, Pardo C, Morera C, Carrió M, Laricchia-Robbio L, Esteban CR, Izpisua Belmonte JC. Characterization of pluripotent stem cells. Nat Protoc 2013; 8:223-53; PMID:23306458; http://dx.doi.org/10.1038/nprot.2012.154
97. Desbaillets I, Ziegler U, Groscurth P, Gassmann M. Embryoid bodies: an in vitro model of mouse embryogenesis. Exp Physiol 2000; 85:645-51; PMID:11187960; http://dx.doi.org/10.1017/S0958067000021047
98. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilić J, Pekarik V, Tiscornia G, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26:1276-84; PMID:18931654; http://dx.doi.org/10.1038/nbt.1503
99. Aran B, Rodríguez-Pizà I, Raya A, Consiglio A, Muñoz Y, Barri PN, Izpisúa JC, Veiga A. Derivation of human embryonic stem cells at the Center of Regenerative Medicine in Barcelona. In Vitro Cell Dev Biol Anim 2010; 46:356-66; PMID:20177997; http://dx.doi.org/10.1007/s11626-010- 9288-0
100. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T, et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med 2012; 1:811-24; PMID:23197693; http://dx.doi.org/10.5966/sctm.2012-0058